Synthesis and anti-breast cancer activity of novel cyclic mono-carbonyl curcumin analogues

FENG Xianhu; CHEN Yongjie; CHEN Lin; HOU Yi; CAO Wanjun; SU Qiang

doi:10.6039/j.issn.1001-0408.2025.05.10

您当前的位置：

首页 >

文章列表页 >

Synthesis and anti-breast cancer activity of novel cyclic mono-carbonyl curcumin analogues

更新时间：2025-03-11

- Synthesis and anti-breast cancer activity of novel cyclic mono-carbonyl curcumin analogues
- ZHONGGUO YAOFANG Vol. 36, Issue 5, Pages: 563-567(2025)
- 作者机构：
  
  1.首都医科大学附属北京安贞医院南充医院·南充市中心医院药学部，四川南充　637500
  2.中江县人民医院临床药学科，四川德阳　618100
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.05.10
  CLC： R914;R965
- Received：10 July 2024，
  
  Revised：31 December 2024，
  
  Accepted：2024-12-31，
  
  Published：15 March 2025
- 稿件说明：
移动端阅览
冯先虎,陈泳洁,陈林等.新型环状单羰姜黄素类似物的合成及其抗乳腺癌活性研究 ^Δ[J].中国药房,2025,36(05):563-567.

FENG Xianhu,CHEN Yongjie,CHEN Lin,et al.Synthesis and anti-breast cancer activity of novel cyclic mono-carbonyl curcumin analogues[J].ZHONGGUO YAOFANG,2025,36(05):563-567.
冯先虎,陈泳洁,陈林等.新型环状单羰姜黄素类似物的合成及其抗乳腺癌活性研究 ^Δ[J].中国药房,2025,36(05):563-567. DOI： 10.6039/j.issn.1001-0408.2025.05.10.

FENG Xianhu,CHEN Yongjie,CHEN Lin,et al.Synthesis and anti-breast cancer activity of novel cyclic mono-carbonyl curcumin analogues[J].ZHONGGUO YAOFANG,2025,36(05):563-567. DOI： 10.6039/j.issn.1001-0408.2025.05.10.

摘要

目的

设计并合成单羰基姜黄素类似物，并考察其抗乳腺癌活性。

方法

通过羟醛缩合反应获得单羰基姜黄素类似物F1、F2和F3，采用MTT法检测其抗肿瘤（包括人乳腺癌细胞MCF-7和人肺癌细胞A549）活性[以半数抑制浓度（IC

）评估

]

，并与姜黄素进行比较。根据生物信息学分析方法分别获取F1、F2和F3作用于乳腺癌的第一核心蛋白，并进行分子对接验证。采用细胞实验进一步考察高、中、低浓度（16、8、4 μmol/L）的F1、F2和F3对MCF-7

细胞中对应第一核心蛋白以及中浓度的F1、F2和F3对细胞中剪切型胱天蛋白酶3（cleaved-caspase-3）表达的影响。

结果

与姜黄素相比，F1、F2和F3对A549、MCF-7细胞的IC

（F2对A549细胞的IC

除外）均显著降低（

＜0.05或

＜0.01），其中F2对MCF-7细胞的IC

最小，为（9.67±1.27）μmol/L。生物信息学分析结果显示，F1、F2和F3与其对应第一核心蛋白表皮生长因子受体（EGFR）、蛋白激酶B（AKT）、AKT的亲和力指数分别为5.909 2、8.402 5和6.486 6。高浓度的F1可显著降低MCF-7细胞中EGFR蛋白磷酸化水平（

＜0.01），低、中、高浓度的F2和高浓度的F3均可显著降低MCF-7细胞中AKT蛋白磷酸化水平（

＜0.05或

＜0.01），中浓度的F1、F2、F3均可显著升高MCF-7细胞中cleaved-caspase-3蛋白表达水平（

＜0.01）。

结论

设计合成的单羰基姜黄素类似物F1、F2、F3均具有良好的抗乳腺癌活性，其中F2的抗乳腺癌活性更好。

Abstract

OBJECTIVE

To design and synthesize mono-carbonyl curcumin analogues（MCACs） and investigate the activities of them against breast cancer.

METHODS

The analogues F1， F2， and F3 were obtained by aldol condensation reaction， and their antitumor activities（including the activities of human breast cancer cell MCF-7 and human lung cancer cell A549） were detected by MTT assay [evaluated with half inhibitory concentration（IC

）

]

. The results of MTT assay were compared with those of curcumin. Bioinformatics methods were used to collect the core targets of analogues F1， F2 and F3 acting on breast cancer， and then molecular docking verification was carried out. The cell experiments were conducted to investigate the effects of high， medium and low concentrations （16， 8， 4 μmol/L） of F1， F2 and F3 on the expression of the first core target protein as well as the effects of medium concentration of F1， F2 and F3 on the expression of cleaved-caspase-3.

RESULTS

Compared with curcumin， IC

of analogues F1， F2 and F3 to A549 and MCF-7 cells（except for IC

of analogue F2 to A549 cells） were decreased significantly（

＜0.05 or

＜0.01）； among them， IC

of analogue F2 to MCF-7 cell was the lowest， being（9.67±1.27） μmol/L. Bioinformatics analysis showed that index of affinity of analogues F1， F2 and F3 with the first core target epidermal growth factor receptor （EGFR）， protein kinase B （AKT） and AKT were 5.909 2， 8.402 5 and 6.486 6， respectively； high concentration of F1 could significantly reduce the phosphorylation level of EGFR protein in MCF-7 cells（

＜0.01）， while low， medium， and high concentrations of F2 and high concentration of F3 could significantly reduce the phosphorylation level of AKT protein in MCF-7 cells（

＜0.05 or

＜0.01）. Medium concentration of F1， F2， and F3 could significantly increase the expression level of cleaved-caspase-3 protein in MCF-7 cells（

＜0.01）.

CONCLUSIONS

Designed and synthesized MCACs F1， F2 and F3 all have good anti-breast cancer activity， and F2 has better anti-breast cancer activity.

关键词

Keywords

references

WILL M ， LIANG J ， METCALFE C ， et al . Therapeutic resistance to anti-oestrogen therapy in breast cancer [J ] . Nat Rev Cancer ， 2023 ， 23 （ 10 ）： 673 - 685 .

THOMAS H R ， HU B ， BOYRAZ B ， et al . Metaplastic breast cancer：a review [J ] . Crit Rev Oncol Hematol ， 2023 ， 182 ： 103924 .

WEI Z C ， CHEN J ， ZUO F ， et al . Traditional Chinese medicine has great potential as candidate drugs for lung cancer：a review [J ] . J Ethnopharmacol ， 2023 ， 300 ： 115748 .

张梦瑶，雷碧黠，解伟，等 . 中药单体抗乳腺癌作用机制进展 [J ] . 上海中医药杂志， 2023 ， 57 （ 6 ）： 26 - 40 .

ZHANG M Y ， LEI B X ， XIE W ， et al . Research progress on mechanism of anti-breast cancer action of Chinese herbal monomers [J ] . Shanghai J Tradit Chin Med ， 2023 ， 57 （ 6 ）： 26 - 40 .

MARTINEZ-CIFUENTES M ， WEISS-LOPEZ B ， SANTOS L S ， et al . Heterocyclic curcumin derivatives of pharmacological interest：recent progress [J ] . Curr Top Med Chem ， 2015 ， 15 （ 17 ）： 1663 - 1672 .

MING T Q ， TAO Q ， TANG S ， et al . Curcumin：an epigene- tic regulator and its application in cancer [J ] . Biomedecine Pharmacother ， 2022 ， 156 ： 113956 .

管红婷，余成浩 . 姜黄素抗肿瘤作用机制的研究进展 [J ] . 中华中医药学刊， 2024 ， 42 （ 4 ）： 143 - 151 .

GUAN H T ， YU C H . Research progress on anti-tumor mechanism of curcumin [J ] . Chin Arch Tradit Chin Med ， 2024 ， 42 （ 4 ）： 143 - 151 .

CHAINOGLOU E ， HADJIPAVLOU-LITINA D . Curcumin in health and diseases：Alzheimer’s disease and curcumin analogues，derivatives，and hybrids [J ] . Int J Mol Sci ， 2020 ， 21 （ 6 ）： 1975 .

MARKAVERICH B M ， SCHAUWEKER T H ， GREGORY R R ， et al . Nuclear type Ⅱ sites and malignant cell proli- feration：inhibition by 2，6-bis-benzylidenecyclohexanones [J ] . Cancer Res ， 1992 ， 52 （ 9 ）： 2482 - 2488 .

TAN K L ， ALI A ， DU Y H ， et al . Synthesis and evaluation of bisbenzylidenedioxotetrahydrothiopranones as activators of endoplasmic reticulum（ER） stress signaling pathways and apoptotic cell death in acute promyelocytic leukemic cells [J ] . J Med Chem ， 2014 ， 57 （ 14 ）： 5904 - 5918 .

SAZDOVA I ， KEREMIDARSKA-MARKOVA M ， DIMITROVA D ， et al . Anticarcinogenic potency of EF24：an overview of its pharmacokinetics，efficacy，mechanism of action，and nanoformulation for drug delivery [J ] . Cancers（Basel）， 2023 ， 15 （ 22 ）： 5478 .

BHANDARI S V ， KUTHE P ， PATIL S M ， et al . A review：exploring synthetic schemes and structure-activity relationship（SAR） studies of mono-carbonyl curcumin analogues for cytotoxicity inhibitory anticancer activity [J ] . Curr Org Synth ， 2023 ， 20 （ 8 ）： 821 - 837 .

ZHAO C G ， LIU Z G ， LIANG G . Promising curcumin-based drug design：mono-carbonyl analogues of curcumin（MACs） [J ] . Curr Pharm Des ， 2013 ， 19 （ 11 ）： 2114 - 2135 .

WEN J ， ZHAO L M ， LI Z H ， et al . Preparation and anti-colon cancer effect of a novel curcumin analogue（CA8）： in vivo and in vitro evaluation [J ] . Front Pharmacol ， 2024 ， 15 ： 1464626 .

陈金铭，蒋清华，陈喆，等 . EGFR在三阴性乳腺癌中的作用及靶向治疗研究进展 [J ] . 肿瘤， 2023 ， 43 （ 10 ）： 829 - 838 .

CHEN J M ， JIANG Q H ， CHEN Z ， et al . Research advances in the roles of EGFR and targeted therapy in triple negative breast cancer [J ] . Tumor ， 2023 ， 43 （ 10 ）： 829 - 838 .

李娜，邓茜，蒋建军 . Akt信号通路在肿瘤中调控机制的研究进展 [J ] . 医学综述， 2022 ， 28 （ 9 ）： 1718 - 1723 .

LI N ， DENG Q ， JIANG J J . Research progress of Akt signaling pathway in regulatory mechanism in tumor [J ] . Med Recapitul ， 2022 ， 28 （ 9 ）： 1718 - 1723 .

LIU J J ， WU F Z ， WANG M H ， et al . Caspase-3-responsive fluorescent/photoacoustic imaging of tumor apoptosis [J ] . Anal Chem ， 2023 ， 95 （ 25 ）： 9404 - 9408 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Zigui yichong formula on premature ovarian insufficiency in mice through glycolytic metabolic pathway

Effects of formononetin on the apoptosis of intestinal epithelial cells in rats with inflammatory bowel disease by regulating the Hippo/YAP signaling pathway

Inhibitory effect and mechanism of total flavonoids from Melicope pteleifolia on transplanted tumor of colorectal cancer in nude mice

Study on inhibitory effects and mechanism of silymarin on glioma in vivo and in vitro

Study on the protective mechanism of Bawei chenxiang powder containing serum on H9c2 cells injured by oxygen-glucose deprivation

Related Author

DUAN Yancang

LIU Xueping

ZHANG Xinmiao

XI Hongyan

TANG Siling

LI Rongxia

WU Zhongyu

XIE Dong

Related Institution

School of Graduate， Hebei University of Chinese Medicine

Hebei Collaborative Innovation Center of Integrated Traditional Chinese and Western Medicine for Reproductive Disease

Hebei Key Laboratory of Integrated Traditional Chinese and Western Medicine for Liver and Kidney Disease Syndrome Research

Dept. of Pharmacy， Tianjin Medical University General Hospital

Dept. of Genetics， School of Basic Medical Sciences， Tianjin Medical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰